Diversified Trust Co Increases Holdings in Gilead Sciences, Inc. $GILD

Diversified Trust Co raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,229 shares of the biopharmaceutical company’s stock after purchasing an additional 8,422 shares during the period. Diversified Trust Co’s holdings in Gilead Sciences were worth $4,798,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GILD. GoalVest Advisory LLC raised its holdings in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the 2nd quarter valued at $27,000. Putney Financial Group LLC raised its holdings in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Howard Hughes Medical Institute bought a new position in Gilead Sciences in the 2nd quarter worth $30,000. Finally, Kilter Group LLC purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth about $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $124.91 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $154.97 billion, a P/E ratio of 19.37, a PEG ratio of 0.69 and a beta of 0.32. The stock’s 50 day moving average is $122.99 and its 200 day moving average is $116.80.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the previous year, the company posted $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the sale, the chief financial officer directly owned 153,503 shares in the company, valued at approximately $18,727,366. This trade represents a 1.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares of the company’s stock, valued at $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 126,257 shares of company stock worth $15,606,892 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Analyst Ratings Changes

GILD has been the topic of several research analyst reports. Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the company an “outperform” rating in a research report on Monday. UBS Group raised Gilead Sciences to a “hold” rating in a research report on Thursday, December 4th. Scotiabank started coverage on Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target on the stock. Morgan Stanley upped their price target on Gilead Sciences from $147.00 to $151.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, Royal Bank Of Canada raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $131.68.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.